Education
About Us
Working with TipRanks
Follow Us
Ainos (AIMD)
NASDAQ:AIMD
AIMD Stock Chart & Stats
$2.28
$0.28(14.00%)
At close: 4:00 PM EST
$2.28
$0.28(14.00%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume448.92K
Average Volume (3M)78.00K
Market Cap
$11.45M
Enterprise Value$17.78M
Total Cash (Recent Filing)$1.13M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding6,982,675
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.40
Price to Sales (P/S)1045.31
P/FCF Ratio-3.72
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue157.28
Enterprise Value/Gross Profit190.21
Enterprise Value/Ebitda-1.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & High Gross MarginSustained top-line recovery with an ~83% gross margin indicates strong unit economics and possible pricing power in core diagnostics. If management maintains scale and mix, gross profits can fund investment in commercialization and reduce reliance on external capital over the medium term.
Multi-year Distribution PartnershipA structured three-year distribution deal with a one-year exclusivity window materially expands regional sales reach and channel capacity. Durable channel partnerships shorten sales cycles, enable repeatable deployments, and support scaling revenue and services over several years.
SmellTech Platform & SLM StrategyA layered hardware/software platform and dedicated Smell Language Model create a durable competitive moat by owning sensor data and enabling recurring SaaS/API monetization. Separation preserves governance and scalability, positioning the company to capture both device and high-margin software revenue as deployments grow.
Bears Say
Persistent Net LossesContinued deep losses undermine self-funded growth and strain returns on invested capital. Persistent negative margins increase dependence on external financing, risk dilution, and may limit the firm's ability to invest in long-term commercialization without improving unit economics or achieving meaningful scale.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow reflects structural cash burn from operations. This reduces financial flexibility, forces reliance on external funding, and can constrain R&D and commercial rollout timelines unless cash generation improves or financing sources are secured on favorable terms.
Rising LeverageA rapid increase in leverage raises interest and covenant risk, reducing balance sheet resilience. Higher debt-to-equity limits financial flexibility for strategic investments and increases the probability that capital-raising or restructuring will be required if operating losses persist over the medium term.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $11.45M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Mar 06, 2026 which is in 4 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Nov 13, 2025. The company reported -$0.644 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.644.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 6,982,675 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.644 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.341%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―